Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Alibaba's Historic $2.8bn Fine Signals Coming Antitrust Wave In China

China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions. 

China Legal Issues

What Does Korea Need To Develop Blockbuster Drugs?

A recent industry forum in South Korea heard expert views on the issues and strategies required to take the country over the finish line in the development of home-grown blockbuster, and to progress the big licensing-out deals reached over the past few years.

South Korea Policy & Regulation

Coronavirus Update: CoVIg-19 Alliance Ends As Trial Misses Endpoints

Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment. 

Coronavirus COVID-19 Research & Development

AI And Tackling Challenges In Clinical Medicine

ISCR conference hears how artificial intelligence and machine learning can address challenges in clinical medicine, especially for cancer, and also optimize clinical trials.

Research & Development Artificial Intelligence

Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights

Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio

Deals M & A

Playing Catchup To US, China Ups COVID Vaccination Pressure

Facing a slow roll-out of COVID-19 vaccines, China is implementing more promotional measures and increasing the pressure on the public to get inoculated. Vaccine diplomacy efforts meanwhile are facing challenges.

China Coronavirus COVID-19
See All

Europe

Set Alert for Europe

Latest From Europe

EMA Expected To Confirm AZ Vaccine Link To Rare Blood Clot

Growing evidence of an association between the vaccine and rare, sometimes fatal blood clots puts Europe’s vaccine program leaders in a difficult position.

BioPharmaceutical Europe

Novavax Plays Down EU COVID Vaccine Contract Delay

Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.

Europe Commercial

Will Serum Institute Join Strides, Gland On The Sputnik V Flight?

While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.

Commercial Coronavirus COVID-19

Could Pfizer Be Dragged Into EU’s Vaccine Dispute With AstraZeneca and UK?

The European Commission is once again threatening to block exports of COVID-19 vaccines to the UK – including those from Pfizer/BioNTech.

Europe Coronavirus COVID-19

Spain's Highlight Has High Hopes For Immuno-Oncology Agent

After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.

StartUps and SMEs ImmunoOncology

New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech

Venture capital firm Arix is financing the Copenhangen, Denmark-based biotech, which is looking to play its part in the fast-maturing gene-editing field.

BioPharmaceutical Europe
See All

United States

Set Alert for United States

Latest From United States

Oncology And US Dominate Daiichi's New Mid-Term Plan

Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.

Business Strategies Research and Development Strategies

Let The Games Begin, Says COVID-19 Vaccine Quad Alliance

A COVID-19 vaccine alliance between US, Japan, India and Australia announced funding for Johnson & Johnson’s vaccine made by Biological E. Will the arrangement be extended to other vaccines and will the alliance push US to address materials export concerns, recently raised by Serum Institute?

Commercial Coronavirus COVID-19

Pharma Gets Warm Spotlight At White House Event Showcasing J&J-Merck Collaboration

Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.

Coronavirus COVID-19 Politics

Setback For Athenex, Hanmi As CRL Requests New Trial

Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.

Cancer Research & Development

ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations

The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.

Vaccines Coronavirus COVID-19

Amid Coronavirus Variants, WHO Urges Continued Vaccination

As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet

Coronavirus COVID-19 Policy & Regulation
See All
UsernamePublicRestriction

Register